drugset / Trial / NCT04470128

A Study Evaluating the Efficacy and Safety of HSK21542 Injection for Analgesia in Subjects Undergoing Colonoscopy

NCT04470128

Phase 2 Completed 180 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, randomized, two-stage, phase II clinical study .The main objective is to evaluate the safety and tolerability of HSK21542 injection for analgesia in patients undergoing colonoscopy, and, combining the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics

Timeline

Start
2020-08-19
Primary completion
2020-12-28
Completion
2021-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK21542 Peptide 0.5 ug/kg Intravenous
Subject HSK21542 Peptide 1 ug/kg Intravenous
Subject HSK21542 Peptide 2 ug/kg Intravenous

Indications

No indication recorded.